Portfolio company
Audentes Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops gene therapy products to treat patients with serious and rare neuromuscular diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
AveXis
This biotechnology firm develops gene therapies for patients with rare and life-threatening neurological genetic diseases including spinal muscular atrophy.
Affinia Therapeutics
This company develops rationally designed gene therapies and viral vectors for patients with heart and central nervous system diseases.
Solid Biosciences
This life science company develops gene therapy candidates for patients living with rare neuromuscular and cardiac diseases.
Neurogene Inc
This company develops genetic medicines and gene therapies to treat patients and families affected by rare neurological diseases including Rett syndrome and Batten disease.
Coave Therapeutics
The company develops targeted gene therapies for patients with neurodegenerative and ocular diseases.
Akouos
The company develops gene therapies to restore, improve and preserve hearing for individuals with disabling sensorineural hearing loss.
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
Dyne
This company develops therapeutics for patients with genetically driven neuromuscular diseases.